Status:
RECRUITING
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
Lead Sponsor:
Yang Xiaotian
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety o...
Detailed Description
This study is a single-arm, prospective, single-center phase IIb clinical efficacy study evaluating the therapeutic effects of azacitidine and venetoclax in combination with granulocyte colony-stimula...
Eligibility Criteria
Inclusion
- Age between 18 and 75 years, regardless of gender.
- Diagnosis of AML (excluding APL) according to the 2022 World Health Organization (WHO) diagnostic criteria.
- ECOG performance status of 0-2.
- For female participants of childbearing potential or male participants with female partners of childbearing potential, effective contraceptive measures must be taken throughout the entire treatment period and for 6 months after the treatment period.
- Expected survival of at least 3 months.
- Ability to understand and willingness to participate in the study, and signing an informed consent form.
Exclusion
- Acute promyelocytic leukemia (M3 subtype).
- Central nervous system leukemia.
- Severe uncontrolled infection or other major diseases.
- Heart failure: Ejection fraction (EF) \< 50%, New York Heart Association (NYHA) class II or above.
- Impaired liver or kidney function: Serum total bilirubin ≥ 2.0 mg/dl, AST ≥ 3 times the upper limit of normal, serum creatinine clearance rate (Ccr) ≥ 50 ml/min, arterial oxygen saturation (SpO2) \< 92%.
- Human immunodeficiency virus (HIV) positive.
- Active hepatitis B or C.
- Pregnant or lactating women.
- Other conditions in which the investigator deems the participant unsuitable for the study.
Key Trial Info
Start Date :
November 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06536010
Start Date
November 3 2021
End Date
July 31 2028
Last Update
August 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huai'an Second People's Hospital
Huai'an, Jiangsu, China, 210000